Fundraising FoxLakewood-Amedex
Sarasota, US · Delaware corporation
Find your way into Lakewood-Amedex
Sign up to see every warm intro you have to Lakewood-Amedex
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Lakewood-Amedex team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Lakewood Amedex develops antimicrobial compounds, specifically Bisphosphocin® formulations, designed as locally delivered bactericides and fungicides with potential medical applications. The company focuses on advancing antimicrobial technology to address infection treatment needs.
Founders & leadership
PA
Paul Anthony DiTullioExecutive
RF
Richard Ford HammExecutive
SP
Steve ParkinsonExecutive
Board
GE
Geoffrey E CoxBoard director
SM
Stephen M MileyBoard director
TW
Teddy Wallace BrownBoard director
Funding
SEC filings, press & company announcements$31.1M disclosed across 3 of 5 rounds · 2014–2026
- Undisclosed amountSeries CMay 2026Source ↗
▶$24.1MraisedJan 2021 · 7 investors · PharmaceuticalsRule 506(b)
▶$24.1MraisedJan 2021 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Steven ParkinsonExecutive Officer, Director
- Geoffrey CoxDirector
- Charles WrightDirector
- Leonard DeRomaDirector
- Peter CorrDirector
- Offering amount
- $40M
- Amount sold
- $24.1M
- Minimum investment
- $250K
- Proceeds to insiders
- $850K
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$456KraisedDec 2019 · 3 investors · PharmaceuticalsRule 506(b)
▶$456KraisedDec 2019 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Steven ParkinsonExecutive Officer, Director
- Patrick Coleman O'ConnorExecutive Officer
- Peter CeccacciExecutive Officer
- Geoffrey Frank CoxDirector
- Leonard James DeRomaDirector
- Charles Frederick WrightDirector
- Offering amount
- $15M
- Amount sold
- $456K
- Minimum investment
- $100K
- Sales commissions
- $12K
- Placement agents
- Sargasso Consulting LLC
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.6MraisedSep 2015 · 75 investors · BiotechnologyRule 506(b)
▶$6.6MraisedSep 2015 · 75 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul Anthony DiTullioExecutive Officer, Director
- Geoffrey E CoxDirector
- Richard Ford HammExecutive Officer
- Steve ParkinsonExecutive Officer, Director
- Stephen M MileyDirector
- Teddy Wallace BrownDirector
- Offering amount
- $10M
- Amount sold
- $6.6M
- Minimum investment
- $26K
- Sales commissions
- $292.6K
- Proceeds to insiders
- $960K
- Placement agents
- Scarsdale Equities LLC, Capital Guardian, LLC
- First sale
- Mar 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Ironwood PharmaceuticalsIronwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focused on developing treatments for GI diseases. It concentrates on GI drug discovery and care for patients suffering from digestive diseases.
IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Companies working in the same space as Lakewood-Amedex.
In the news
Frequently asked questions
- What does Lakewood-Amedex do?
- Lakewood Amedex develops antimicrobial compounds, specifically Bisphosphocin® formulations, designed as locally delivered bactericides and fungicides with potential medical applications. The company focuses on advancing antimicrobial technology to address infection treatment needs.
- How much funding has Lakewood-Amedex raised?
- Lakewood-Amedex has disclosed $31.1M raised across 3 of its 5 known rounds.
- Where is Lakewood-Amedex headquartered?
- Lakewood-Amedex is headquartered in Sarasota, US.